- Home
- IMNM vs PENG Comparison
IMNM vs PENG Comparison
Compare IMNM & PENG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | PENG |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IMNM | PENG |
|---|---|---|
| Price | $28.01 | $50.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $32.80 | $27.78 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 05-08-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.40 | ★ 128.00 |
| EPS | N/A | ★ 1.29 |
| Revenue | $6,941,000.00 | ★ $1,368,794,000.00 |
| Revenue This Year | N/A | $14.55 |
| Revenue Next Year | $1,127.34 | $16.14 |
| P/E Ratio | ★ N/A | $40.79 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.67 | $16.04 |
| 52 Week High | $30.06 | $89.86 |
Technical Indicators
Market Signals| Indicator | IMNM | PENG |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 41.61 |
| Support Level | $18.72 | $17.48 |
| Resistance Level | N/A | $53.27 |
| Average True Range (ATR) | 1.51 | 3.72 |
| MACD | 0.15 | -0.46 |
| Stochastic Oscillator | 66.25 | 10.37 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
About PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.